Braidwell led a $168m Series A round in Caris Life Sciences.

Braidwell, a life science-focused investment firm, led a $168m Series A round in Caris Life Sciences, a next-generation AI TechBio company. "Caris puts the patient at the center of everything we do. This raise will help us bring our market-leading science and technologies to as many patients as possible and further our goal of revolutionizing precision medicine. We plan to unlock the full potential of precision medicine by comprehensively interrogating cancer at the molecular level and enabling the delivery of transformative applications of molecular science," David D. Halbert, Caris Chairman, Founder and CEO.